Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Int. braz. j. urol ; 42(6): 1190-1194, Nov.-Dec. 2016. graf
Artigo em Inglês | LILACS | ID: biblio-828942

RESUMO

ABSTRACT Objective: Previous series have demonstrated that Clomiphene Citrate (CC) is an effective treatment to increase Total Testosterone (TT) in Late Onset Hypogonadism (LOH) patients. However, what happens to TT levels after ending CC treatment is still debatable. The objective of this study is to evaluate TT levels 3 months after the discontinuation of CC in patients with LOH who were previously successfully treated with the same drug. Materials and Methods: Twenty-seven patients with LOH that were successfully treated (achieved TT levels >11nmol/l) with CC 50mgs daily for 50 days were prospectively recruited in our Andrological outpatient clinic. CC was then stopped for 3 months and TT levels were measured at the end of this period. Results: Mean TT level before discontinuation of CC was 22.7±8.1nmol/L (mean±SD). Three months after discontinuation, mean TT level significantly decreased in all patients, 10.2±3.9nmol/l (p<0.01). Twenty-one patients (78%) decreased TT levels under 11nmol/L. Six patients (22%) had TT levels that remained within the normal recommended range (≥11nmol/l). No statistical significant differences were observed between both groups. Conclusion: In the short term LOH does not seem to be a reversible condition in most patients after CC treatment. More studies with longer follow-up are needed to evaluate the kinetics of TT in LOH.


Assuntos
Humanos , Adulto , Idoso , Testosterona/sangue , Clomifeno/uso terapêutico , Antagonistas de Estrogênios/uso terapêutico , Hipogonadismo/terapia , Hormônio Luteinizante/sangue , Estudos Prospectivos , Seguimentos , Resultado do Tratamento , Clomifeno/administração & dosagem , Antagonistas de Estrogênios/administração & dosagem , Hormônio Foliculoestimulante/sangue , Hipogonadismo/cirurgia , Pessoa de Meia-Idade
2.
Int. braz. j. urol ; 38(4): 512-518, July-Aug. 2012. ilus, tab
Artigo em Inglês | LILACS | ID: lil-649445

RESUMO

INTRODUCTION: Male testosterone deficiency is associated with bad sexual function and quality of life (QoL). The aim of this study was to determine whether a daily dose of 25 mg clomiphene citrate (CC) is effective in stimulating the endogenous testosterone production pathway and to address the applicability of this medication as a therapeutic option for symptomatic hypogonadism. MATERIALS AND METHODS: This was a prospective study. Men with low sexual desire and testosterone levels (T) below 400 ng/dL were selected to receive CC. Blood samples were obtained to determine baseline measurements of serum T, estradiol, LH, lipid profile and fasting plasma glucose. Each patient was treated with a daily dose of 25 mg CC for at least 3 months. Patients were asked if they experienced any side effects related to the use of CC and if they experienced any improvement in their sexual profile. Paired samples T-test was utilized to analyze responses to therapy. RESULTS: Our cohort consisted of 125 men with hypogonadism and low libido. Mean age was 62 years (± 11.1 years). Serum T levels ranged from 309 ng/dL (baseline, mean value) to 642 ng/dL (3 months after CC initiation, mean value) (p < 0.001). Serum cholesterol levels ranged from 197 to 186 mg/dL (p = 0.003). There were no statistically significant differences when comparing pre and post-treatment HDL-Cholesterol, triglycerides, fasting plasma glucose and prolactin. All men reported improvements in the post-treatment QoL scores. No serious adverse events were recorded. CONCLUSIONS: The CC was effective in stimulating the endogenous production of testosterone. A lower level of total cholesterol was verified after three months of treatment. This medication should be considered as a therapeutic option for some patients with symptomatic male testosterone deficiency.


Assuntos
Adulto , Idoso , Humanos , Masculino , Pessoa de Meia-Idade , Clomifeno/administração & dosagem , Antagonistas de Estrogênios/administração & dosagem , Hipogonadismo/tratamento farmacológico , Testosterona/deficiência , Fatores Etários , Métodos Epidemiológicos , Luminescência , Qualidade de Vida , Fatores de Tempo , Resultado do Tratamento , Testosterona/sangue , Testosterona/metabolismo
4.
Journal of Korean Medical Science ; : 445-451, 2008.
Artigo em Inglês | WPRIM | ID: wpr-69845

RESUMO

We initiated this study to investigate whether combining Helicobacter pylori eradication with immunosuppressive therapy provides an additional benefit to patients with idiopathic thrombocytopenic purpura (ITP) that has relapsed or has not responded to steroid and/or danazol therapy in patients who have H. pylori infection. Thirty- four patients with chronic ITP that had relapsed or failed to steroid and/or danazol therapy were assessed for H. pylori infection. Of the 21 confirmed cases, 12 patients were given H. pylori eradication therapy alone (EA), while 9 patients received eradication therapy combined with immunosuppressive therapy (EI). The response rate was not significantly different between patients in the EA and those in the EI group (41.7% in the EA group vs. 66.7% in the EI group, p=0.345). The median platelet count at 6 months after therapy was higher in the EI group patients (75X10(9)/L in the EI group patients vs. 18x109/L in the EA group patients, p=0.028). The median response duration was also longer in the EI group patients (9 months in the EI group patients vs. 3 months in the EA group patients, p=0.049). These results show that a significant benefit is gained by the use of H. pylori eradication combined with immunosuppressive therapy over the use of eradication therapy alone for patients with chronic ITP.


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Antibacterianos/administração & dosagem , Doença Crônica , Danazol/administração & dosagem , Quimioterapia Combinada , Antagonistas de Estrogênios/administração & dosagem , Infecções por Helicobacter/complicações , Helicobacter pylori , Imunossupressores/administração & dosagem , Púrpura Trombocitopênica Idiopática/complicações , Esteroides/administração & dosagem , Resultado do Tratamento
5.
Artigo em Inglês | IMSEAR | ID: sea-44458

RESUMO

OBJECTIVE: To determine the day of ovulation by the salivary ferning test in clomiphene citrate-treated women. DESIGN: A descriptive study. SETTING: Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. SUBJECT: Seventy-five infertile women with regular menstrual cycles. MATERIAL AND METHOD: Infertile women were given 100 mg of clomiphene citrate for five days and collected their saliva samples daily until seven days after ovulation. Transvaginal ultrasound was performed daily to detect ovulation. The salivary ferning formation was examined by a normal light microscope and graded from 1-3, according to its extent and intensity. MAIN OUTCOME MEASURE: The salivary ferning score, the peak salivary ferning day, and the day of ovulation detected by ultrasound. RESULTS: The patients' age and cycle length (mean +/- SD) were 32.9 +/- 3.7 years and 28.4 +/- 1.3 days. The peak salivary ferning day corresponded with the ultrasound ovulation day in only 7.1%. There were two peaks of median salivary ferning scores; one was two days prior ovulation and the other was five days post ovulation. There was no correlation between the peak salivary ferning day and day of ovulation detected by ultrasound (r = 0.102, p > 0.05). CONCLUSION: In clomiphene citrate-stimulated cycles, the saliva ferning test does not seem to associate with ovulation.


Assuntos
Adulto , Clomifeno/administração & dosagem , Endométrio/efeitos dos fármacos , Antagonistas de Estrogênios/administração & dosagem , Feminino , Fármacos para a Fertilidade Feminina/administração & dosagem , Hormônio Foliculoestimulante , Humanos , Infertilidade Feminina/diagnóstico por imagem , Hormônio Luteinizante , Ciclo Menstrual/efeitos dos fármacos , Ovulação/efeitos dos fármacos , Detecção da Ovulação/métodos , Indução da Ovulação , Saliva , Tailândia , Tempo
6.
Arq. bras. oftalmol ; 67(4): 631-635, jul.-ago. 2004. tab, graf
Artigo em Português | LILACS | ID: lil-386034

RESUMO

OBJETIVO: O tamoxifeno é um antiestrógeno utilizado como agente terapêutico eficaz no câncer de mama. A droga pode causar efeitos tóxicos oculares em dosagens altas. O objetivo deste estudo foi determinar possíveis efeitos retino-tóxicos centrais usando o eletrorretinograma multifocal (mfERG) em grupo de pacientes tratadas com baixa dosagem de tamoxifeno (20 mg/dia) após cirurgia do câncer de mama. MÉTODOS: O eletrorretinograma multifocal (mfERG) de 30 graus centrais da retina foi obtido em 3 diferentes grupos: Grupo experimental - 15 mulheres (41-59 anos, média 48,6 ± 4,5) com fundo de olho normal, tratadas com tamoxifeno em baixa dosagem por 1 a 55 meses. Grupo controle - 6 mulheres (30 -76 anos, média 49,9±18,8) com diagnóstico prévio de câncer de mama que não receberam tratamento com tamoxifeno até o teste do eletrorretinograma multifocal. Grupo controle normal - 15 voluntárias normais (30-71 anos, média 47,7 ± 12,9). A amplitude e a latência de eletrorretinograma multifocal para N1-P1 foram analisados estatisticamente (análise de variância de uma via). RESULTADOS: As amplitudes médias N1-P1 (nV/grau²) foram comparáveis para respostas de diferentes excentricidades (0 a 25 graus) nos três grupos. Não houve diferença estatisticamente significativa para a latência de N1 e P1 (ms) do eletrorretinograma multifocal entre os 3 grupos. CONCLUSÕES: O tratamento com baixa dosagem de tamoxifeno não mostrou efeitos retino-tóxicos em pequeno grupo de mulheres após cirurgia do câncer de mama. Investigação seriada proporcionará melhor compreensão desses efeitos.


Assuntos
Humanos , Feminino , Adulto , Pessoa de Meia-Idade , Antagonistas de Estrogênios/efeitos adversos , Antagonistas de Estrogênios/toxicidade , Neoplasias da Mama , Eletrorretinografia , Retina , Tamoxifeno , Antagonistas de Estrogênios/administração & dosagem , Tamoxifeno
7.
P. R. health sci. j ; 23(1): 13-18, Mar. 2004.
Artigo em Inglês | LILACS | ID: lil-359654

RESUMO

Hereditary (HAE) and acquired (AAE) angioedema are vascular reactions involving the sub mucosal tissues, representing localized edema caused by dilatation and increased permeability of the capillaries. HAE and AAE are clinical disorders characterized by angioedema that require prompt differentiation from other causes of angioedema in order to receive the most pertinent and effective therapeutic interventions. The aim of this report is to describe the clinical characteristics of patients with both HAE and AAE identified and followed at the Immunology Clinic of the University Hospital at the Puerto Rico Medical Center, their response and side effects to danazol therapy and their comparison with other series of similar patients reported in the literature. Overall, the patients in this sample presented a similar clinical profile compared to other reported series in the literature.


Assuntos
Humanos , Masculino , Feminino , Criança , Adolescente , Adulto , Pessoa de Meia-Idade , Angioedema , Antagonistas de Estrogênios/administração & dosagem , Antagonistas de Estrogênios/efeitos adversos , Antagonistas de Estrogênios/uso terapêutico , Complemento C1 , Complemento C1q , Complemento C4 , Interpretação Estatística de Dados , Diagnóstico Diferencial , Danazol/administração & dosagem , Danazol/efeitos adversos , Danazol/uso terapêutico , Ensaio de Imunoadsorção Enzimática , Imunodifusão , Inativadores do Complemento/análise , Fatores de Tempo
8.
J Indian Med Assoc ; 2001 Aug; 99(8): 436, 438-40
Artigo em Inglês | IMSEAR | ID: sea-96475

RESUMO

Endometriosis is defined as the presence of tissue, histologically similar to endometrium, in any other site but that of uterine cavity. Transplantation of endometrial tissue that comes as a retrograde menstrual flow is the most accepted possible theory. Endometriosis is associated with marked subfertility, but the mechanism of causation of infertility is poorly understood unless it has caused very definite anatomical distortion of internal genitalia. Management of infertility in endometriosis is discussed in detail.


Assuntos
Adulto , Idoso , Danazol/administração & dosagem , Endometriose/complicações , Antagonistas de Estrogênios/administração & dosagem , Feminino , Hormônio Liberador de Gonadotropina/administração & dosagem , Humanos , Incidência , Índia/epidemiologia , Infertilidade Feminina/epidemiologia , Pessoa de Meia-Idade , Progesterona/administração & dosagem , Prognóstico , Fatores de Risco , Índice de Gravidade de Doença
9.
J. bras. ginecol ; 100(8): 249-50, ago. 1997. tab
Artigo em Português | LILACS | ID: lil-197969

RESUMO

Quarenta e seis pacientes com carcinoma avançado de mama foram tratadas com antiestrogênio (Tamoxifen) no Setor de Patologia Mamária do HCPA. Após quatro anos. 35 pacientes apresentavam seguimento adequado para tabulaçäo dos resultados quanto à eficácia do tratamento, duraçäo da resposta e efeitos colaterais. Os autores concluem que o tratamento com Tamoxifeno é a primeira escolha em hormonioterapia na pós-menopausa, para tratamento do câncer de mama


Assuntos
Humanos , Feminino , Antagonistas de Estrogênios/administração & dosagem , Antagonistas de Estrogênios/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/terapia , Pós-Menopausa , Tamoxifeno/administração & dosagem , Tamoxifeno/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA